Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinibSAN FRANCISCO, ...
In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...
Nurix Therapeutics (NRIX) announced the appointment of John Northcott as chief commercial officer. From 2022 through 2024, Mr. Northcott served ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...
Just because a business does not make any money, does not mean that the stock will go down. For example, Nurix Therapeutics (NASDAQ:NRIX) shareholders have done very well over the last year, with the ...
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback